Publication Name	World Journal of Gastroenterology
Manuscript ID	23061
Country	Canada

Received	2015-10-17 13:50
Peer-Review Started	2015-10-17 19:15
To Make the First Decision	2015-11-13 09:32
Return for Revision	2015-11-13 15:51
Revised	2015-11-27 15:50
Second Decision	2015-12-18 16:06
Accepted by Journal Editor-in-Chief	2015-12-21 13:03
Accepted by Company Editor-in-Chief	2015-12-30 17:44
Articles in Press	2015-12-30 17:44
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-03-02 15:39
Publish the Manuscript Online	2016-03-14 08:44

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Metastatic gastric cancer treatment: Second line and beyond
Manuscript Source	Unsolicited Manuscript
All Author List	Marwan Ghosn, Samer Tabchi, Hampig Raphael Kourie and Mustapha Tehfe
Funding Agency and Grant Number
Corresponding Author	Dr. Mustapha Tehfe, Department of Medical Oncology, Centre Hospitalier de l'Université de Montréal, 2900 Boulevard Edouard-Montpetit, Montréal, QC H3T 1J4, Canada. matohfe@gmail.com
Key Words	Advanced gastric cancer; Treatment; Second-line; Cytotoxic; Targeted therapy
Core Tip	Patients with advanced gastric cancer who progress after first line therapy are usually perceived as unfit for additional treatments and are therefore denied life prolonging treatments which can also improve quality of life. We herein review the available evidence in favor of undertaking therapeutic interventions in these patients, be it conventional cytotoxic therapies or targeted therapies.
Publish Date	2016-03-14 08:44
Citation	Ghosn M, Tabchi S, Kourie HR, Tehfe M. Metastatic gastric cancer treatment: Second line and beyond. World J Gastroenterol 2016; 22(11): 3069-3077
URL	http://www.wjgnet.com/1007-9327/full/v22/i11/3069.htm
DOI	http://dx.doi.org/10.3748/wjg.v22.i11.3069

Full Article (PDF)	WJG-22-3069.pdf
Full Article (Word)	WJG-22-3069.doc
Manuscript File	23061-Review.docx
Answering Reviewers	23061-Answering reviewers.pdf
Audio Core Tip	23061-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	23061-Conflict-of-interest statement.pdf
Copyright License Agreement	23061-Copyright assignment.pdf
Peer-review Report	23061-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	23061-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	23061-Scientific misconduct check.pdf
Scientific Editor Work List	23061-Scientific editor work list.pdf